Leveling the Compliance Playing Field - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Leveling the Compliance Playing Field
The author suggests industry may need a NATO-type organization to even out inspections.


Pharmaceutical Technology
Volume 6, Issue 34, pp. 69, 70

Finding a solution

We have seen both scenarios among our clients. Is this a level playing field? Is it in a company's best interest to relocate its production to a foreign, ideally non-English speaking, country to attract less FDA scrutiny? Because of lower compliance costs, the company's cost of production will also be lower, in addition to any other related lower costs based on the local economy.

Considering the global nature of the pharmaceutical business and the merits of free trade, global inspection standards are needed and should be uniformly enforced. The current supply chain has become so long that breaches are occuring more frequently, with no end in sight. Unfortunately, a long supply chain can lead to fragmented inspection scrutiny. Should regulators discourage such complicated production schemes under the justification that they are too risky and too difficult to control? Supply-chain breeches cast doubt on the industry, harm its credibility, and reduce consumer confidence in products—just look at the recent consumer angst over the H1N1 vaccine.

The International Conference on Harmonization (ICH), the Global Harmonization Task Force (GHTF) for medical devices, and the pharmacopeia have made good progress on establishing global standards. But global standards are only as good as global enforcement, because too much profit is available to those who cut corners. FDA has a major, but not all-encompassing, global inspection program. The Europeans have a significant foreign inspection program.And other countries perform some foreign inspections, but is this enough? Consider the following:
  • Perhaps the countries setting the global standards also need to set global enforcement standards backed with adequate inspection resources
  • Perhaps each country should contribute resources for enforcing compliance in proportion to its size
  • Similar to the way ICH sets harmonized standards for product applications, perhaps the organization could also agree on the depth and breadth of global inspections
  • Perhaps all inspectors from around the world should have a standard amount of time to spend on site, ask the same questions, request (and be able to understand) the same number of documents, and arrive at similar conclusions based on what they have seen—would this require a global inspectors' training program?
  • Perhaps all good manufacturing practice documents should be required to be in the local language and in one of a handful of major world languages that would be used by the majority of inspectors.

There is precedent for developed countries to cooperate on enforcement—for example, to protect global human rights. The UN and the North Atlantic Treaty Organization oversee such collaboration. How about an ICH Inspectorate?

Paul Larocque is president of Acerna Inc. in Ontario, http://www.Acerna.ca/,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here